This is a multicenter, two part (Part A and Part B) clinical study of CMP-001 administered
intratumorally (IT) and subcutaneously (SC) in combination with atezolizumab with or without
radiation therapy in participants with NSCLC.
This study will be conducted in two parts, run sequentially: Part A of the study will
evaluate the safety and preliminary signs of efficacy for the combination of CMP-001 and
atezolizumab. Part B of the study will evaluate the addition of radiation therapy to the
combination of CMP-001 and atezolizumab.
Each part of the study will follow a Simon 2-stage Optimal Design approach. Part A and Part B
of the study will commence with a safety run in of 5 participants treated with the
combination treatment (CMP-001 and atezolizumab in Part A; and CMP-001, atezolizumab and
radiation therapy in Part B). After the first 5 participants have passed a safety
dose-limiting toxicity (DLT) observation period of 30 days and upon approval from the Safety
Review Committee (SRC), both parts of the study will continue with enrollment of an
additional 7 participants in each part to complete Stage 1 of respective parts. If an
acceptable safety profile is established and at least 2 responders out of 12 evaluable
participants (that is, complete and partial responders based on Response Evaluation Criteria
in Solid Tumors [RECIST] version 1.1 [v1.1] or RECIST v1.1 for immune-based therapeutics
[iRECIST] criteria) in Stage 1), the study will enroll an additional 23 evaluable
participants in Stage 2 of each part. A maximum of 35 evaluable participants will be enrolled
in each Part A and Part B.
Participants enrolled in Part A with documented progression per RECIST v1.1 on the
combination of CMP-001 and atezolizumab have the option to receive radiation therapy add-on
treatment after documented disease progression per computed tomography (CT)/magnetic
resonance imaging (MRI) or positron emission tomography (PET) scan. The total number of
participants enrolled into the Part A optional radiation therapy add-on may not exceed the
total number of participants enrolled in Part A. Enrollment of participants in Part A
optional radiation therapy add-on will not effect enrollment in Part B of the study as these
participants will be evaluated separately.
Participants will continue treatment with CMP-001 in combination with atezolizumab as long as
they do not experience unacceptable toxicities and when, according to the Investigator,
continued treatment is in the participant's best interest.
- Histopathologically confirmed diagnosis of metastatic NSCLC.
- Documented disease progression on prior programmed cell death-1/programmed
death-ligand 1 (PD-1/PD-L1) therapy in any line. Participants must have received a
minimum of 4 doses of anti-PD-1/PD-L1 therapy before enrolling into the CMP-001-003
study. If participants have received fewer than 4 doses of anti-PD-1/PD-L1 therapy,
documented radiologic progression and sponsor approval is necessary prior to
- Participants with epidermal growth factor (EGFR) activating mutations, EGFR T790M or
anaplastic lymphoma kinase (ALK) gene re-arrangement must have received prior standard
of care and have evidence of disease progression. With the exception of participants
with squamous cell cancer, EGFR and ALK status must be known prior to enrollment.
- Participants must have at least one extra-central nervous system (CNS), non-bone tumor
lesion amenable for IT injection greater than or equal to (>=) 1.5 centimeters (cm)
and that is not in close proximity or encasing crucial structures such as major blood
vessels, trachea, nerve bundles.
- Measurable disease per RECIST version 1.1.
- Capable of understanding and complying with protocol requirements.
- A life expectancy of greater than 24 weeks at Screening.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1 at Screening.
- Most recent laboratory values within 2 weeks prior to Week 1 Day 1 meet the following
1. Bone marrow function: Neutrophil count >=1,500/ cubic millimeters (mm^3) without
granulocyte colony stimulating factor; Platelet count >=100,000/mm^3 without
transfusion; Hemoglobin concentration >=9.0 grams per deciliter (g/dL).
2. Liver function: Total bilirubin less than or equal to (<=) 2.0 times the upper
limit of normal (ULN) of each institution with the exception of participants with
Gilbert Disease serum bilirubin >= 3 * ULN; Aspartate aminotransferase (AST) and
alanine aminotransferase (ALT) <=2.5 times the ULN with the following exceptions:
participants with documented liver metastases; AST and ALT <=5 * ULN.
3. Renal function: serum creatinine <=1.5 times the ULN.
4. Lactate dehydrogenase (LDH) <=2 times ULN.
5. Partial thromboplastin time (PTT) and international normalized ratio (INR):
Activated PTT (aPTT) <=1.5 * ULN, unless related to lupus anticoagulant.
Participants receiving unfractionated heparin must have aPTT between 1.5 and 2.5
* ULN or determined by their physician; INR < =1.5 * ULN. Participants receiving
warfarin should have INR between 2.0 and 3.0 or within a range determined by
- The participant must sign a written informed consent form prior to the initiation of
any study procedures. Adult participants unable to provide written informed consent on
their own behalf will not be eligible for the study.
- For participants enrolled in Part B, metastatic lesions must be accessible for
radiation therapy (that is, no direct overlap of the current treatment).
- Pregnant or breastfeeding
- Received investigational therapy (that is, small molecule or biologic) within 30 days
prior to the start of CMP-001 dosing on Week 1 Day 1. However, if an investigational
therapy has a short half-life, a reduced wash out period may be acceptable with
Sponsor approval. Acceptable washout periods for non-investigational therapy include:
1. 3-14 days from prior tyrosine kinase inhibitor (TKI) depending on half-life.
2. 3 weeks from prior chemotherapy.
3. 1 week for prior palliative radiation therapy, or 2 weeks if prior brain
4. Received treatment with anti- cytotoxic T-lymphocyte-associated protein 4
(anti-CTLA-4) antibody within 30 days prior to the start of CMP-001.
5. 14 days for prior PD-1 therapy.
- Known infection with human immunodeficiency virus (HIV), hepatitis B virus (HBV) or
hepatitis C virus (HCV). If there is no known or documented history of HIV, HBV or
HCV, the site is not required to do additional testing for these values at Screening.
- Developed autoimmune disorders of Grade 4 while on prior immunotherapy. Participants
who developed autoimmune disorders, of Grade <=3 may enroll if the disorder has
resolved to Grade <=1 and the participant has been off systemic steroids at doses
greater than (>) 10 milligrams per day (mg/day), for the treatment of the autoimmune
disorder, for at least 2 weeks.
- Require systemic pharmacologic doses of corticosteroids greater than the equivalent of
10 mg/day prednisone; topical, ophthalmologic and inhalational steroids are permitted.
Participants who have a history of adrenal insufficiency and are receiving greater
than 10 mg/day prednisone may be eligible but only after Sponsor consultations.
Participants who are currently receiving steroids at a dose of <=10 mg/day do not need
to discontinue steroids prior to enrollment.
- Active (that is, symptomatic or progressing) CNS metastases. However, participants
with active CNS metastases are eligible for the trial if:
1. The metastases have been treated by surgery and/or radiotherapy.
2. The participant is off corticosteroids of >10 mg/day prednisone or equivalent.
3. The participant is neurologically stable for at least 2 weeks prior to Screening.
4. Brain MRI completed within 6 weeks of Screening (required for all participants).
- Any concurrent uncontrolled illness, including mental illness or substance abuse,
which in the opinion of the Investigator, would make the participant unable to
cooperate or participate in the trial.
- Severe uncontrolled cardiac disease within 6 months of screening, including but not
limited to uncontrolled hypertension; unstable angina; myocardial infarction (MI) or
cerebrovascular accident (CVA).
- Requires prohibited treatment (that is., non-protocol specified anticancer
pharmacotherapy, surgery or conventional radiotherapy for treatment of malignant
tumor). Limited field single dose radiotherapy for pain palliation would be allowed at
any time during the course of treatment.
- Women of childbearing potential who are unable or unwilling to use an acceptable
method of contraception.
- Requires continuous anti-coagulation or anti-platelet therapy that cannot be safely
interrupted to allow for IT injection and/or history of coagulopathy.
- History of another malignancy except for:
1. Malignancy treated with curative intent and with no known active disease >5 years
prior to the start of CMP-001 dosing on Week 1 Day 1 and of low potential risk
2. Adequately treated non-melanoma skin cancer or lentigo maligna without evidence
3. Adequately treated carcinoma in situ without evidence of disease (for example,
cervical cancer in situ), superficial bladder cancer, squamous cell carcinoma of
the skin, basal cell carcinoma of the skin.
4. Other concurrent low-grade malignancies such as chronic lymphocytic leukemia
(CLL) (Rai 0) may be considered after discussion and permission from Sponsor.